NCT00424086已完成1 期
Single Blind, Randomized, Actively Controlled Phase 1/2 Study to Compare the Safety and Immunogenicity of a Split Virus, Vero Cell Derived, Seasonal Influenza Vaccine (VCIC) With a Licensed, Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 1,000
- 试验地点
- 16
- 主要终点
- To assess the immunogenicity of Vero cell derived vaccine in comparison to egg-derived vaccine for subjects in two age strata: 18 to 49 years of age and 50 years of age and older
研究概览
简要总结
The objective of this study is to assess the safety, tolerability and immunogenicity of a Split Virus, Vero Cell derived, Seasonal Influenza Vaccine (VCIV) in comparison to a Licensed Egg Derived, Split Virus, Seasonal Influenza Vaccine (EIV) in healthy subjects 18 years of age and older.
Approximately 1000 subjects will be randomly assigned in a 3:1 ratio to receive a single injection of VCIV or EIV. Subjects will be monitored for 180 days following vaccination for occurrence of adverse reactions and for antibody response to the vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects who
- •Are 18 to 49 years of age (inclusive) on the day of screening (Stratum A)
- •Are 50 years of age or older on the day of screening (Stratum B)
- •Have an understanding of the study, agree to its provisions, and give written informed consent prior to study entry
- •Are clinically healthy (in a physical condition such that the physician would have no reservations administering influenza vaccine outside the scope of a clinical study)
- •Are physically and mentally capable of participating in the study
- •Agree to keep a daily record of symptoms
- •If female and capable of bearing children, have a negative urine pregnancy test result within 24 hours of the vaccination on Study Day 0 and agree to employ adequate birth control measures. For the purposes of this study adequate birth control measures incorporate 2 types of the following FDA approved birth control measures through 60 days after vaccination:
- •Hormonal types of birth control (such as implants, birth control pills, patches or other methods) or an intrauterine device, AND
- •An additional barrier type of birth control measure (i.e., condoms, diaphragms, cervical caps, etc.)
排除标准
- •Subjects who
- •Have previously been vaccinated against influenza with vaccine formulated for the 2006/2007 influenza season
- •Have an oral temperature >=37.5°C at the time of vaccination on Day 0 (see note below)
- •Have Type I diabetes
- •Have a Body Mass Index >35
- •Have hypertension at screening (with or without medication) that is graded as greater than Stage 1 defined as a systolic pressure >159 or diastolic pressure >99 while seated and at rest (measurement may be repeated twice before subject is absolutely excluded)
- •Have clinically significant abnormal clinical laboratory values at screening
- •Have clinically significant electrocardiographic abnormalities at screening
- •Test positive for Human Immunodeficiency Virus(HIV), Hepatitis B Surface Antigen (HbsAg) or Hepatitis C Virus (HCV)
- •Have a history of cardiovascular disease that required hospitalization
- •Have a history of immunodeficiency or autoimmune diseases
- •Have a history of arthritis (joint swelling, tenderness, warmth or erythema) on more than one occasion, not related to trauma (including running) or any episode of non-trauma related arthritis within the previous 6 months
- •Suffer from active neoplastic disease or have a history of hematologic malignancy
- •Suffer from a disease or are undergoing a form of treatment that can be expected to influence immune response. Such treatment includes, but is not limited to systemic or high dose inhaled (>800 μg/day of beclomethasone dipropionate or equivalent) corticosteroids, radiation treatment or other immunosuppressive or cytotoxic drugs
- •Have a history of inflammatory or degenerative neurological disease (e.g. Guillain Barré, multiple sclerosis)
- •Have received any vaccination within 2 weeks prior to vaccination in this study
- •Have received a blood transfusion or immunoglobulins within 30 days prior to vaccination in this study
- •Have donated blood or plasma within 30 days prior to vaccination in this study
- •Have a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to eggs, allergy to components of the test or comparator vaccine, other known contraindications)
- •Have a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating
- •Have a positive urine drug screen (unless the detected drug is currently prescribed by a licensed health care provider and the continued administration of the drug would not otherwise exclude the subject from participation)
- •Were administered an investigational drug within 6 weeks prior to study entry
- •Are concurrently participating in a clinical study that Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)includes the administration of an investigational product
- •Are a member of the team conducting this study
- •Are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator
- •If female, are pregnant or lactating.
- •NOTE: If all other inclusion/exclusion criteria are met, a subject with a temperature >=37.5°C on Day 0 may be included in the study at a repeat visit provided:
- •They do not have an oral temperature >=37.5°C at the repeat visit,
- •The repeat visit is no more than 5 calendar days after the initial Day 0 visit,
- •The repeat visit is no more than 21 calendar days after all other screening procedures are completed,
- •Subjects are still being recruited at the study site.
结局指标
主要结局
To assess the immunogenicity of Vero cell derived vaccine in comparison to egg-derived vaccine for subjects in two age strata: 18 to 49 years of age and 50 years of age and older
To assess the safety and tolerability of Vero cell derived vaccine in comparison to egg-derived vaccine in healthy subjects in two age strata: 18 to 49 years, and 50 years of age and older
次要结局
未报告次要终点
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in ChildrenInfluenzaNCT00900991Sinovac Biotech Co., Ltd
已完成
3 期
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.Influenza, HumanNCT02914275Seqirus2,250
已完成
2 期
Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in AdolescentsInfluenzaNCT00900588Sinovac Biotech Co., Ltd
已完成
3 期
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of AgeInfluenza, HumanNCT02545543Seqirus2,278
已完成
4 期
A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersInfluenza, HumanNCT01863433Seqirus120